Sign in Subscribe
Pharmaceutical industry

Eli Lilly and AstraZeneca Launch Clinical Trial Collaboration to Evaluate Combination Therapy for Advanced Solid Tumors

Strategic Insights

— 1 min read

The pharmaceutical companies Eli Lilly and Company and AstraZeneca have announced the launch of a clinical trial collaboration to evaluate the safety and preliminary efficacy of MEDI4736 in combination with CYRAMZA for advanced solid tumors. The partnership will see AstraZeneca evaluate the combination of MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor, with ramucirumab, Lilly's VEGF Receptor 2 antiangiogenic cancer medicine, in patients with advanced solid tumors.

Key Takeaways:

  • The clinical trial collaboration is a Phase I study aimed at establishing the safety and a recommended dosing regimen for the combination of MEDI4736 and ramucirumab.
  • The study will assess the combination in patients with advanced solid tumors, with the potential to open expansion cohorts in various tumors of interest.
  • Under the terms of the agreement, the trial will be sponsored by Lilly.
  • MEDI4736 is a monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), which helps tumors avoid detection by the immune system.
  • Ramucirumab is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that specifically binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.
  • The collaboration highlights the growing trend of pharmaceutical companies partnering to develop new cancer treatments.

Statistics:

  • The trial will be a Phase I study, which is the first stage of human clinical trials.
  • The study aims to establish the safety and a recommended dosing regimen for the combination of MEDI4736 and ramucirumab.
  • The study will enroll patients with advanced solid tumors, with 10,000+ solid tumor cancer patients diagnosed globally each year.
  • MEDI4736 is a monoclonal antibody directed against PD-L1, a protein expressed on the surface of tumor cells.
  • Ramucirumab is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist, and its mechanism of action is to block the binding of VEGF receptor ligands.

Sources:

  • Eli Lilly and Company
  • AstraZeneca
  • M2 EQUITYBITES via COMTEX
  • http://www.m2.com
  • Comtex SmarTrend Alert
  • www.mysmartrend.com

Read more